Prevalence and Risk Factors of COVID-19 Reinfection in Patients with Rheumatoid Arthritis: A Retrospective Observational Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To identify the prevalence and risk factors of coronavirus disease 2019 (COVID-19) reinfection in patients with rheumatoid arthritis (RA). Materials and Methods: This study retrospectively analyzed patients with RA with a documented COVID-19 infection between January 2021 and December 2022 at a tertiary hospital in Seoul, South Korea. Reinfection was defined as a subsequent positive test result for severe acute respiratory syndrome coronavirus 2 at least 3 months after the initial infection. Cox proportional hazards models with backward elimination were employed to assess the association between potential risk factors and risk of reinfection. Results: Of 351 included patients with RA {female, 81.5%; median age, 58.0 years [interquartile range (IQR), 48.0–66.0]}, 252 (71.8%) were treated with methotrexate and 12 (3.4%) received leflunomide during the initial infection. Over a median follow-up of 1.5 (IQR, 1.1–1.6) years, 43 (12.3%) patients experienced reinfection, equating to an incidence rate of 8.97 per 100 patient-years. The median time interval between infections was 0.8 (IQR, 0.6–1.2) years. Among the risk factors, leflunomide use showed a significant association with reinfection (hazard ratio, 2.968; 95% confidence interval, 1.057–8.335; p=0.039). However, no significant changes occurred in disease activity following reinfection [disease activity score using 28 joints: baseline median, 2.3 (IQR, 1.9–2.8); post-reinfection median, 2.3 (IQR, 1.8–2.6), p for change=0.895]. Conclusion: In this retrospective cohort study of patients with RA with COVID-19 infection, approximately 12% of patients experienced reinfection without significant change in disease activity. Leflunomide use was associated with a higher risk of reinfection.
Abstract
Purpose: To identify the prevalence and risk factors of coronavirus disease 2019 (COVID-19) reinfection in patients with rheumatoid arthritis (RA). Materials and Methods: This study retrospectively analyzed patients with RA with a documented COVID-19 infection between January 2021 and December 2022 at a tertiary hospital in Seoul, South Korea. Reinfection was defined as a subsequent positive test result for severe acute respiratory syndrome coronavirus 2 at least 3 months after the initial infection. Cox proportional hazards models with backward elimination were employed to assess the association between potential risk factors and risk of reinfection. Results: Of 351 included patients with RA {female, 81.5%; median age, 58.0 years [interquartile range (IQR), 48.0–66.0]}, 252 (71.8%) were treated with methotrexate and 12 (3.4%) received leflunomide during the initial infection. Over a median follow-up of 1.5 (IQR, 1.1–1.6) years, 43 (12.3%) patients experienced reinfection, equating to an incidence rate of 8.97 per 100 patient-years. The median time interval between infections was 0.8 (IQR, 0.6–1.2) years. Among the risk factors, leflunomide use showed a significant association with reinfection (hazard ratio, 2.968; 95% confidence interval, 1.057–8.335; p=0.039). However, no significant changes occurred in disease activity following reinfection [disease activity score using 28 joints: baseline median, 2.3 (IQR, 1.9–2.8); post-reinfection median, 2.3 (IQR, 1.8–2.6), p for change=0.895]. Conclusion: In this retrospective cohort study of patients with RA with COVID-19 infection, approximately 12% of patients experienced reinfection without significant change in disease activity. Leflunomide use was associated with a higher risk of reinfection.
참고문헌 (21)
- Zhong J, "COVID-19 in patients with rheumatic disease in Hubei province, China : a multicentre retrospective observational study", Lancet Rheumatol, 2, pp.e557~e564 (2020)
- Shin YH, "Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea : a nationwide cohort study", Lancet Rheumatol, 3, pp.e698~e706 (2021)
- Cohen C, "COVID-19 infection, reinfection, and the transition to endemicity", Lancet, 401, pp.798~800 (2023)
- Deng L, "Risk of SARS-CoV-2 reinfection : a systematic review and meta-analysis", Sci Rep, 12, pp.20763~ (2022)
- Slezak J, "Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients", Clin Microbiol Infect, 27, pp.1860~ (2021)
- Perrot L, "First flare of ACPA-positive rheumatoid arthritis after SARSCoV-2 infection", Lancet Rheumatol, 3, pp.e6~e8 (2021)
- Di Iorio M, "DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease : a prospective study", Semin Arthritis Rheum, 55, pp.152025~ (2022)
- Wong AC, "Serotonin reduction in post-acute sequelae of viral infection", Cell, 186, pp.4851~4867 (2023)
- Aletaha D, "2010 rheumatoid arthritis classification criteria : an American College of Rheumatology", European League Against Rheumatism collaborative initiative, 2010, pp.62, 2569~2581
- Singh JA, "2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis", Arthritis Rheumatol, 68, pp.1~26 (2016)
- Bongartz T, "Incidence and mortality of interstitial lung disease in rheumatoid arthritis : a population-based study", Arthritis Rheum, 62, pp.1583~1591 (2010)
- Babiker A, "The importance and challenges of identifying SARS-CoV-2 reinfections", J Clin Microbiol, 59, pp.e02769-20~ (2021)
- Lee SW, "Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea : a nationwide cohort study", Lancet Psychiatry, 7, pp.1025~1031 (2020)
- Choi BY, "Insights from the COVID-19 pandemic : underscoring the paramount value of patient education and counseling for rheumatic diseases", J Rheum Dis, 31, pp.59~61 (2024)
- Abu-Raddad LJ, "Assessment of the risk of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)reinfection in an intense reexposure setting", Clin Infect Dis, 73, pp.e1830~e1840 (2021)
- Markov PV, "The evolution of SARS-CoV-2", Nat Rev Microbiol, 21, pp.361~379 (2023)
- Nguyen NN, "High rate of reinfection with the SARS-CoV-2 Omicron variant", J Infect, 85, pp.174~211 (2022)
- Yousefghahari B, "Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs", Clin Rheumatol, 40, pp.4309~4315 (2021)
- Hu K, "A smallscale medication of leflunomide as a treatment of COVID-19 in an open-label blank-controlled clinical trial", Virol Sin, 35, pp.725~733 (2020)
- Conigliaro P, "The type I IFN system in rheumatoid arthritis", Autoimmunity, 43, pp.220~225 (2010)